Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE

OLAUGIO PM

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

2. Address Check if different than previously reported				
1440 New York Avenu	ue, N.W. Washington, [D.C. 20005		
3. Principal Place of Business (if differ	ent from line 2)			
City:	State/Zip (or Country)			
4. Contact Name Brian D. Flynn	Telephone E (202)371-7000		mail (optional)	5. Senate ID# 35560-1
7. Client Name			6. House ID# 317060	
Check if this filing amends a p	oreviously filed version of this	Date		
. Check if this filing amends a p	oreviously filed version of this	report Date		
TYPE OF REPORT Check if this filing amends a part of the content	oreviously filed version of this n Report	DateLine 12 OR L	ine 13	11. No Lobbyii
Check if this filing amends a position. Check if this is a Termination of the control of the co	oreviously filed version of this n Report	DateLine 12 OR L EXPENSES reperiod were:	ine 13 13. Organisting to lobbying	11. No Lobbyi
Check if this filing amends a positive of the control of the contr	oreviously filed version of this n Report	Date Line 12 OR L EXPENSES re period were: Less than \$10,00	ine 13 13. Organisting to lobbying	11. No Lobbyi
Check if this filing amends a part of the content o	oreviously filed version of this n Report	DateLine 12 OR L EXPENSES reperiod were:	13. Organism 13.	11. No Lobbyi
Check if this filing amends a part of the content o	oreviously filed version of this n Report □ ⇒ Termination NSES - Complete Either ing Firms activities for this reporting 20,000 Income (nearest \$20,000)	Date Line 12 OR L EXPENSES re period were: Less than \$10,00 \$10,000 or more 14. REPORTI	ine 13 13. Organisting to lobbying 00 □ □ □ ⇒ \$ NG METHOD. (11. No Lobbyi
O. Check if this filing amends a provide a good faith estimate, reof all lobbying related income	oreviously filed version of this n Report □ ⇒ Termination NSES - Complete Either ing Firms activities for this reporting 20,000 Income (nearest \$20,000) ounded to the nearest \$20,000, from the client (including all	Date Line 12 OR L EXPENSES reperiod were: Less than \$10,00 \$10,000 or more 14. REPORTI accounting methods	ine 13 13. Organism of the lating to lobbying of the lating to lobbying of the lating to lobbying of the lating to lobby in lating to la	11. No Lobbyii
O. Check if this filing amends a provide a good faith estimate, respectively.	oreviously filed version of this n Report □ ⇒ Termination NSES - Complete Either ing Firms activities for this reporting 20,000 Income (nearest \$20,000) nunded to the nearest \$20,000, from the client (including all any other entity for lobbying	Date Line 12 OR L EXPENSES reperiod were: Less than \$10,00 \$10,000 or more 14. REPORTI accounting method A.	ine 13 13. Organizating to lobbying 00	11. No Lobbying the Lobbying the Lobbying Lobbying the Lobbying Lobbying the Lobbying

Filing #b2d9e372-9ebc-4132-ae5b-398a26609d2a - Page 1 of 4

Registrant Name Skadden, Arps, Slate, Meagher & Flom Client N	Name Glaxo Smith Kline
LOBBYING ACTIVITY. Select as many codes as necess engaged in lobbying on behalf of the client during the repo information as requested. Attach additional page(s) as need	rting period. Using a separate page for each cod
15. General issue area code HCR (one per page)	•
16. Specific lobbying issues Metered Dose Inhaler Transition Issues	
17. House(s) of Congress and Federal agencies contacted U.S. House of Representatives U.S. Senate EPA State Department	☐ Check if None
18. Name of each individual who acted as a lobbyist in thi	is issue area Covered Official Position (if applicable)
James A. Losey	
······································	
19. Interest of each foreign entity in the specific issues listed on	· · · ·
Glaxo Wellcome, Inc, owned by Glaxo Wellcome, PLC, sel ensure transition policy for MDI's that protect patient and pl	ls pharmaceutical products in the U.S. and abroad hysician access to essential medical treatment opti
Signature Janeth Losey	
Printed Name and Title James A. Losey, Partner	